Oxis Turbuhaler (Formoterol Fumarate Dihydrate)

Formoterol fumarate dihydrate is a bronchodilator that acts on the airway smooth‑muscle pathway to improve airflow.

• Asthma: improves long‑term control of symptoms and reduces the frequency of exacerbations.
• Chronic obstructive pulmonary disease (COPD): enhances lung function and decreases rescue‑inhaler use.
• Exercise‑induced bronchoconstriction: provides pre‑exercise bronchodilation for patients with reactive airway disease.

• Formoterol binds selectively to β2‑adrenergic receptors on airway smooth‑muscle cells, activating adenylate cyclase and increasing cyclic AMP levels. The rise in cAMP leads to relaxation of smooth‑muscle fibers, producing sustained bronchodilation that lasts up to 12 hours after inhalation.

Formoterol may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects

• Tremor: mild shaking of the hands or limbs.
• Headache: transient head discomfort.
• Throat irritation: mild soreness or dryness in the throat.
• Cough: occasional dry cough after inhalation.
• Palpitations: sensation of rapid or irregular heartbeat.
• Nausea: mild stomach upset.

Serious or Rare Side Effects

• Paradoxical bronchospasm: sudden worsening of breathing difficulty.
• Cardiac arrhythmia: irregular heart rhythm that may require medical attention.
• Hypokalemia: low blood potassium levels detectable on laboratory testing.
• Severe allergic reaction: rash, itching, swelling, or difficulty breathing.
• Hyperglycaemia: elevated blood glucose, particularly in diabetic patients.
• Pulmonary hypertension: increased pressure in lung arteries, observed rarely.

When using Oxis Turbuhaler, patients and healthcare providers should consider several safety measures.

• Assess asthma/COPD severity: confirm that maintenance therapy with a LABA is appropriate.
• Review cardiovascular history: patients with arrhythmias or ischemic disease need careful monitoring.
• Monitor potassium levels: especially in patients on diuretics or with renal impairment.
• Avoid abrupt discontinuation: sudden stopping may worsen bronchospasm.
• Educate on inhaler technique: proper use maximises drug delivery and reduces local irritation.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Formoterol may interact with several drug classes, altering its safety or efficacy profile.

Major Interactions (Avoid)

• Beta‑blockers: can diminish bronchodilator effect and precipitate bronchospasm.
• Monoamine oxidase inhibitors (MAOIs): may increase risk of cardiovascular side effects.

Moderate Interactions (Monitor Closely)

• Diuretics: can exacerbate hypokalemia when combined with a LABA.
• Theophylline: may increase the likelihood of tremor and tachycardia.
• Anticholinergics: additive bronchodilation may require dose adjustment of one agent.
• Corticosteroids inhaled: while not a direct interaction, combined use is common and requires monitoring for systemic effects.
• Certain antidepressants (e.g., SSRIs): may modestly raise heart rate when used together.